Wu Nan, Zhang Zhen, Zhou Xi, Zhao Hengqiang, Ming Yue, Wu Xue, Zhang Xian, Yang Xin-Zhuang, Zhou Meng, Bao Hua, Chen Weisheng, Wu Yong, Liu Sen, Wang Huizi, Niu Yuchen, Li Yalun, Zheng Yu, Shao Yang, Gao Na, Yang Ying, Liu Ying, Li Wenli, Liu Jia, Zhang Na, Yang Xu, Xu Yuan, Li Mei, Sun Yingli, Su Jianzhong, Zhang Jianguo, Xia Weibo, Qiu Guixing, Liu Yong, Liu Jiaqi, Wu Zhihong
Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Beijing Key Laboratory for Genetic Research of Skeletal Deformity, Beijing, China.
J Cell Mol Med. 2020 May;24(9):4931-4943. doi: 10.1111/jcmm.14991. Epub 2020 Apr 11.
Tumour-induced osteomalacia (TIO) is a very rare paraneoplastic syndrome with bone pain, fractures and muscle weakness, which is mostly caused by phosphaturic mesenchymal tumours (PMTs). Cell-free DNA (cfDNA) has been regarded as a non-invasive liquid biopsy for many malignant tumours. However, it has not been studied in benign tumours, which prompted us to adopt the targeted next-generation sequencing approach to compare cfDNAs of 4 TIO patients, four patients with bone metastasis (BM) and 10 healthy controls. The mutational landscapes of cfDNA in TIO and BM groups were similar in the spectrum of allele frequencies and mutation types. Markedly, deleterious missense mutations in FGFR1 and loss-of-function mutations in MED12 were found in 3/4 TIO patients but none of BM patients. The gene ontology analysis strongly supported that these mutated genes found in TIOs would play a potential role in PMTs' process. The genetic signatures and corresponding change in expression of FGFR1 and FGF23 were further validated in PMT tissues from a test cohort of another three TIO patients. In summary, we reported the first study of the mutational landscape and genetic signatures of cfDNA in TIO/PMTs.
肿瘤诱导的骨软化症(TIO)是一种非常罕见的副肿瘤综合征,伴有骨痛、骨折和肌肉无力,主要由磷酸尿性间叶肿瘤(PMT)引起。游离DNA(cfDNA)已被视为许多恶性肿瘤的非侵入性液体活检方法。然而,尚未在良性肿瘤中进行研究,这促使我们采用靶向二代测序方法比较4例TIO患者、4例骨转移(BM)患者和10名健康对照者的cfDNA。TIO组和BM组cfDNA的突变图谱在等位基因频率谱和突变类型方面相似。值得注意的是,在4例TIO患者中有3例发现了FGFR1的有害错义突变和MED12的功能丧失突变,而BM患者中均未发现。基因本体分析有力地支持了在TIO中发现的这些突变基因在PMT过程中可能发挥作用。在另外3例TIO患者的测试队列的PMT组织中进一步验证了FGFR1和FGF23的基因特征及相应的表达变化。总之,我们报告了第一项关于TIO/PMT中cfDNA突变图谱和基因特征的研究。